Tumefactive multiple sclerosis (TMS): clinical features
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Tumefactive multiple sclerosis (TMS): clinical features. This accounts for about 1-3 per 1000 cases of MS. Fully referenced neurology checklist.
Demographic features
- This accounts for about 1-3 per 1000 cases of MS
- It especially occurs in the third to fourth decades of life
- The affected patients are young and are more likely to be female
Possible triggers
Locked: subscribe to see this section.
Clinical features
Locked: subscribe to see this section.
Outcome
Locked: subscribe to see this section.
Poor prognostic features
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: a comprehensive review. Mult Scler Relat Disord 2017; 14:72-79.
- Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008; 131:1759-1775.
- Hardy TA, Chataway J. Tumefactive demyelination: an approach to diagnosis and management. JNNP 2013; 84:1047-1053.
- Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 2013; 81:1654-1658.
- Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012; 79:2000-2003.
- And 8 more. Subscribe to see the full list
